Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.37 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1823720 | 0.84 | GABRA1 (0.50) | GABRA1GABRB2CA2CYP1A2CYP2C9 | |
| SCHEMBL1823721 | 0.84 | GABRA1 (0.50) | GABRA1GABRB2CA2CYP1A2CYP2C9 | |
| SCHEMBL1678604 | 0.83 | AR (0.37) | CYP3A4MAPTPADI4ERN1 | |
| SCHEMBL29397237 | 0.79 | CYP3A4 (0.42) | CYP1A2CYP2C9CYP2C19ALDH1A1POLB | |
| SCHEMBL3966986 | 0.79 | CYP3A4 (0.42) | CYP1A2CYP2C9CYP2C19ALDH1A1POLB | |
| SCHEMBL6346480 | 0.76 | GABRA1 (0.32) | GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL4650198 | 0.75 | CYP3A4 (0.44) | CYP1A2ALDH1A1POLBSMN1; SMN2CYP3A4 | |
| SCHEMBL3461711 | 0.74 | GABRA1 (0.64) | GABRA1GABRB2CA2CYP1A2CYP2C9 | |
| SCHEMBL8936229 | 0.74 | GABRA1 (0.31) | GABRA1GABRB2ALDH1A1TSHRPTGS1 | |
| SCHEMBL1825677 | 0.74 | PTGS1 (0.50) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960303-B1 | INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATTER, AND HIGH-MOLECULAR-WEIGHT POLYMERIZATION INITIATOR | FUJIFILM CORP (JP) | 2019-10-09 | — | — | EP | disclosed |
| US-9902865-B2 | Ink composition, inkjet recording method, printed matter, and high-molecular-weight polymerization initiator | FUJIFILM CORPORATION (JP) | 2018-02-27 | — | — | US | disclosed |
| EP-2960303-A1 | INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATTER, AND HIGH-MOLECULAR-WEIGHT POLYMERIZATION INITIATOR | Fujifilm Corporation (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-20150344711-A1 | INK COMPOSITION, INKJET RECORDING METHOD, PRINTED MATTER, AND HIGH-MOLECULAR-WEIGHT POLYMERIZATION INITIATOR | FUJIFILM CORPORATION (JP) | 2015-12-03 | — | — | US | disclosed |
| CN-104995266-A | Ink composition, ink jet recording method, printed matter, and polymer polymerization initiator | FUJIFILM CORP | 2015-10-21 | — | — | CN | disclosed |
| US-8093349-B2 | Terminally modified polybranched polyimide, metal-plated terminally modified polybranched polyimide, and method for producing the same | UBE INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-2097388-B1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS LLC (US) | 2011-09-07 | — | — | EP | disclosed |
| US-7915299-B2 | 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100063122-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMlDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-11 | — | — | US | disclosed |
| US-20100009206-A1 | TERMINALLY MODIFIED POLYBRANCHED POLYIMIDE, METAL-PLATED TERMINALLY MODIFIED POLYBRANCHED POLYIMIDE, AND METHOD FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| EP-2097388-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | High Point Pharmaceuticals, LLC (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008059026-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMIDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063122-A1 | NOVEL 2-(2-HYDROXYPHENYL)BENZIMlDAZOLES USEFUL FOR TREATING OBESITY AND DIABETES | GPR119, HAGH, ALDH2 | GABRA1 1185/4885GABRB2 424/4885CA2 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.